SCHEMBL4886787

SCHEMBL4886787

O=C1COc2ccccc2N1CC(O)CO

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.65
WDR77 Q9BQA1 1/20 0.65
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
TSHR P16473 2/20 0.52
ALDH1A1 P00352 3/20 0.50
POLB P06746 2/20 0.50
LMNA P02545 1/20 0.50
ALOX12 P18054 1/20 0.50
CBX7 O95931 2/20 0.49
CDYL2 Q8N8U2 2/20 0.49
CDYL Q9Y232 2/20 0.49
CDY1; CDY1B Q9Y6F8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
HTT P42858 1/20 0.48
USP2 O75604 1/20 0.48
KDM4E B2RXH2 1/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4095894 0.84 ALOX12 (0.55) PRMT5WDR77KMT2AMEN1TSHR
SCHEMBL4098137 0.84 ALOX12 (0.55) PRMT5WDR77KMT2AMEN1TSHR
SCHEMBL4109925 0.84 ALOX12 (0.55) PRMT5WDR77KMT2AMEN1TSHR
SCHEMBL11826964 0.81 KMO (0.60) KMT2AMEN1TSHRPOLBHTT
SCHEMBL15836136 0.79 PRMT5 (1.00) PRMT5WDR77ALDH1A1POLBLMNA
SCHEMBL7358743 0.79 ALDH1A1 (0.61) KMT2AMEN1TSHRALDH1A1POLB
SCHEMBL4091136 0.76 ALOX12 (0.52) PRMT5WDR77KMT2AMEN1TSHR
SCHEMBL4096320 0.76 TSHR (0.54) PRMT5WDR77KMT2AMEN1TSHR
SCHEMBL4100847 0.76 ALOX12 (0.52) PRMT5WDR77KMT2AMEN1TSHR
SCHEMBL4100523 0.76 TSHR (0.54) PRMT5WDR77KMT2AMEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759342-B2 Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US disclosed
US-8759342-B2 Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US disclosed
US-8759342-B2 Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US disclosed
US-20080039454-A1 Urotensin II receptor antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2008-02-14 US disclosed
WO-2008016534-A1 UROTENSIN II RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039454-A1 Urotensin II receptor antagonists UTS2R, PLAUR, NTSR2 PRMT5 3343/4885WDR77 2292/4885KMT2A 3204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.